Enfuvirtide: First fusion inhibitor for treatment of HIV infection

American Journal of Health-System Pharmacy

Volumn 61, Issue 12, 2004, Pages 1242-1247

  Jamjian, M Christine ^a   McNicholl, Ian R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Antiretroviral agents; Costs; Drug distribution; Drugs, availability; Enfuvirtide; HIV infections; Mechanism of action; Pharmacokinetics; Toxicity

Indexed keywords

CD4 ANTIGEN; ENFUVIRTIDE; RIFAMPICIN; SAQUINAVIR;

AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; CELL COUNT; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG MARKETING; EOSINOPHILIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; INJECTION SITE REACTION; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION;

EID: 8344271311     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.12.1242     Document Type: Review

References (28)

1. Fuzeon (enfuvirtide) package insert. Durham, NC: Trimeris; 2003.
2. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med. 2002; 348:2228-38.
3. Eckert DM, Kim PS. Mechanism of viral membrane fusion and its inhibition. Annu Rev Biochem. 2001; 70:777-810.
4. Cooley LA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol. 2003; 26:121-32.
5. Gulick RM. New antiretroviral drugs. Clin Microbiol Infect. 2003; 9:186-93.
6. Zhang X, Nieforth K, Lang JM et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther. 2002; 72:10-9.
7. Kilby JM, Lalezari JP, Eron JJ et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retrovir. 2002; 18:685-93.
8. Kilby JM, Hopkins S, Venetta TM et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998; 4:1302-7.
9. Lalezari JP, Eron JJ, Carlson M et al. Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003; 17:691-8.
10. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003; 348:2175-85.
11. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug resistant HIV-1 in Europe and Australia. N Engl J Med. 2003; 348:2186-95.
12. Katlama C, Arasteh K, Clotet B et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. Paper presented at Second International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; 2003 Jul 14.
13. Trottier B, Arasteh K, Henry K et al. Durability of response of enfuvirtide through 48 weeks in the TORO trials. Paper presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003 Sep 15.
14. Delfraissy JF, Montaner J, Eron J et al. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 Phase III trials in highly antiretroviral (ARV) treatment-experienced patients. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb 12.
15. Montaner J, DeMasi R, Delehanty J et al. Analysis of virological response of enfuvirtide in TORO: implications for patient management. Paper presented at Second International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; 2003 Jul 14.
16. Battegay M, DeMasi R, Delehanty J et al. Analysis of virological failure through 24 weeks of treatment in the TORO 1 and TORO 2 studies. Paper presented at Second International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; 2003 Jul 14.
17. Drobnes C, Fang L, Nelson E et al. Tolerability of enfuvirtide (T-20) during chronic therapy in Phase II trials. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 2002 Sep 27.
18. Eron J, Delfraissy JF, Kuritzkes D et al. Safety of enfuvirtide (ENF) through 48 weeks of therapy in the TORO trials. Paper presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003 Sep 15.
19. Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. J Antimicrob Chemother. 2003; 51:213-7.
20. Ball R, Kinchelow T, for the ISR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol. 2003; 49:826-31.
21. Reeves JD, Gallo SA, Ahmad N et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA. 2002; 99:16249-54.
22. Zollner B, Feucht HH, Schroter M et al. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS. 2001; 15:935-6.
23. Roman F, Gonzalez D, Lambert C et al. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr. 2003; 33: 134-9.
24. Wei X, Decker JM, Liu H et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46:1896-905.
25. Boyd M, Ruxrungtham K, Zhang X et al. Enfuvirtide: investigations on the drug interaction potential in HIV-infected patients. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb 12.
26. Boyd M, Zhang X, Dorr A et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 2003; 43:1382-91.
27. Cohen CJ, Dusek A, Green J et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDs. 2002; 16:327-35.
28. Lalezari JP, Patel IH, Zhang X et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) I HIV-1 infected patients. J Clin Virol 2003; 28:217-22.